Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
doi: 10.1016/j.mito.2019.12.005 416 NaviauxRK
Using more products than your skin can tolerate may overload your skin, potentially causing inflammation, damaging your skin barrier and making your condition worse
The antibiotic treatment decreased the relative abundance of Firmicutes, a SCFA producing phylum of bacteria in the gut, which correlates with a decrease in SCFA concentrations and an increase in BBB permeability [148]
Back in 2006, when I first became Wisconsins Medicaid Director, the view of most within the Medicaid world was that it wasnt Medicaids job to fill the gaps caused by a quickly retreating social welfare system